A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

In pediatric-onset multiple sclerosis, switching to oral or infusion therapies was linked to fewer relapses than switching between injectable treatments.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.